Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation
- PMID: 10921510
- DOI: 10.1023/a:1007068313370
Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation
Abstract
We have previously reported the antifibrotic effects of pirfenidone (PD) in the bleomycin (BL)-hamster model of lung fibrosis. Since the development of fibrosis is generally preceded by acute lung inflammation, the present study was conducted to find out if dietary intake of PD (0.5%) has any effects on BL-induced lung inflammation. In this regard, we evaluated the effects of PD on BL-induced increased pulmonary vascular permeability, increased influx of inflammatory cells and increased levels of TGF-beta in the bronchoalveolar lavage fluid (BALF). Hamsters were intratracheally (IT) instilled with saline (SA) or BL (5.5 units/kg/5 ml). The animals were fed the control diet (CD) or the same diet containing 0.5% PD 2 days prior to IT instillation and throughout the study. The bronchoalveolar lavage was carried out at different times after IT instillation. Lavage fluid was used for total and differential cell counts and BALF-supernatant for measurement of total protein and TGF-beta. IT instillation of BL caused significant increases in total cells, neutrophils, macrophages and lymphocytes and in the levels of total protein and TGF-beta in BALF from hamsters in the BL + CD groups as compared to the corresponding SA + CD control groups. In contrast, treatment with pirfenidone in general, suppressed the BL-induced increases in the levels of proteins and TGF-beta and in the influx of neutrophils, macrophages and lymphocytes in BALF at the early time points in BL + PD groups. Based on the data reported in this study, we conclude that the anti-inflammatory effects of pirfenidone as evident by suppressions of BL-induced increased pulmonary vascular permeability and increased influx of inflammatory cells in the lung contribute additionally to its inherent anti-fibrotic effect.
Similar articles
-
Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.J Pharmacol Exp Ther. 1999 Oct;291(1):367-73. J Pharmacol Exp Ther. 1999. PMID: 10490926
-
Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.J Pharmacol Exp Ther. 1999 Apr;289(1):211-8. J Pharmacol Exp Ther. 1999. PMID: 10087006
-
Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis.Biochem Pharmacol. 1997 Dec 1;54(11):1205-16. doi: 10.1016/s0006-2952(97)00343-2. Biochem Pharmacol. 1997. PMID: 9416971
-
Pirfenidone for the treatment of idiopathic pulmonary fibrosis.Expert Opin Investig Drugs. 2006 Jul;15(7):823-8. doi: 10.1517/13543784.15.7.823. Expert Opin Investig Drugs. 2006. PMID: 16787145 Review.
-
Antifibrotic activities of pirfenidone in animal models.Eur Respir Rev. 2011 Jun;20(120):85-97. doi: 10.1183/09059180.00001111. Eur Respir Rev. 2011. PMID: 21632796 Free PMC article. Review.
Cited by
-
Pathogenesis and Therapy of Hermansky-Pudlak Syndrome (HPS)-Associated Pulmonary Fibrosis.Int J Mol Sci. 2024 Oct 19;25(20):11270. doi: 10.3390/ijms252011270. Int J Mol Sci. 2024. PMID: 39457053 Free PMC article. Review.
-
Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.Drugs. 2015 Feb;75(2):219-30. doi: 10.1007/s40265-015-0350-9. Drugs. 2015. PMID: 25604027 Review.
-
Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.Respir Res. 2019 Jan 15;20(1):10. doi: 10.1186/s12931-019-0974-5. Respir Res. 2019. PMID: 30646908 Free PMC article.
-
Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones.Molecules. 2012 Jan 17;17(1):884-96. doi: 10.3390/molecules17010884. Molecules. 2012. PMID: 22252504 Free PMC article.
-
Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.Mol Ther. 2021 Apr 7;29(4):1487-1500. doi: 10.1016/j.ymthe.2021.01.028. Epub 2021 Jan 26. Mol Ther. 2021. PMID: 33508432 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical